Cigna Corporation (CI) AI Stock Analysis

Cigna Corporation delivers insurance and health services solutions across the United States and internationally. It operates through two primary segments: Evernorth and Cigna Healthcare. Evernorth provides health services including pharmacy benefits management, care delivery management, benefits coordination, and health intelligence solutions tailored for health plans, employers, government entities, and providers. Cigna Healthcare offers medical, pharmacy, behavioral health, dental, vision, and advocacy programs to insured and self-insured customers. It also provides Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, alongside individual plans on and off public exchanges. Founded in 1792, Cigna distributes its offerings through brokers, consultants, direct sales, unions, and healthcare exchanges.

Cigna grew annual revenue from $174.07B in FY2021 to $274.95B in FY2025, reflecting a 5-year revenue CAGR of 11.4%. Growth surged 26.6% in FY2024 to $247.12B before increasing 11.3% in FY2025. Gross margin declined from 13.2% in FY2021 to 9.5% in FY2025, while operating margin contracted from 4.6% to 3.3% over the same period. Net income stood at $5.96B in FY2025 with net margin of 2.2%, supporting diluted EPS of $29.85. In the latest quarter ended June 30, 2026, revenue increased 6.7% year-over-year, and quarterly earnings grew 10.2%.

As of June 30, 2026, Cigna held $6.30B in cash and short-term investments against $31.88B in total debt, resulting in net debt of $25.58B. Shareholders' equity was $42.62B, yielding a debt-to-equity ratio of 0.75 and a current ratio of 0.85. In FY2025, the company generated $9.60B in operating cash flow and $8.39B in free cash flow. Capital expenditures totaled $1.21B, while capital returns included $3.62B in share buybacks and $1.61B in dividends paid. Cigna's share count was reduced by 19.9% over five years.

At $302.30, Cigna trades at a trailing P/E of 12.5x and a forward P/E of 8.3x, compared to the median of its S&P 500 Healthcare peers of 28.9x and 16.6x, respectively. Its enterprise value of $95.60B implies an EV/EBITDA multiple of 7.6x, below the peer group median of 15.7x, while price-to-sales is 0.3x versus the peer median of 3.4x. Cigna has posted a 1-year return of 6.2% and a 5-year return of 60.9%, trailing the S&P 500 (SPY) gains of 16.8% and 83.0% over the respective periods.

Cigna pays a quarterly dividend with an annual forward payout of $6.24, representing a dividend yield of 2.06%. The payout ratio is 19.7%. Cigna has paid consecutive dividends for 45 years, with its most recent ex-dividend date on September 8, 2026.

Wall Street coverage includes 12 Strong Buy, 6 Buy, and 6 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $342.29, representing 13.2% upside compared to the last close of $302.30. Consensus estimates project FY2026 revenue of $287.45B with EPS of $30.51, followed by $299.16B in revenue and EPS of $33.48 for FY2027. Cigna beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Cigna Corporation (CI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CI income statement, CI balance sheet, CI key metrics, CI analyst forecast, CI chart. See the CI stock overview for the latest quote and news.